Phase 4 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with hemophilia A with inhibitors (where the body's immune system blocks the clotting treatment). People who have previously had high levels of inhibitors must still have a detectable inhibitor level at the time of enrollment (confirm with trial site for specific measurements)
- People aged between 12 and 65 years
- People who have had at least three bleeding episodes into their joints in the past six months
- People who have signed a consent form agreeing to take part
Who may not be able to join:
- People who have any other bleeding disorder, whether they were born with it or developed it over time
- People whose liver or kidney function test results are above a certain level, as shown in recent blood tests (confirm with trial site for specific values)
- People who are currently receiving a treatment called immune tolerance induction (ITI) therapy and whose inhibitor levels are below a certain threshold at the time of enrollment (confirm with trial site)
- People who have previously had a blood clot (such as a deep vein thrombosis, stroke, or similar event)
- People who have a known history of drug allergies, asthma, hives, or other significant allergic conditions
- People whom the trial doctor considers unsuitable for participation, for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8615620988690
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Efficacy of prothrombin complex concentrate (PCC) in the treatment of bleeding episodes in patients with hemophilia A with inhibitors.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.